Previous 10 | Next 10 |
home / stock / lly / lly articles
Goldman Sachs analysts re-rated Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), citing the potential for their weight-loss drugs. The ...
The Nasdaq 100 closed lower by over 100 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders sell share...
Wednesday, the FDA granted accelerated approval to Eli Lilly And Co’s (NYSE:LLY) selpercatinib (Retevmo) for pediatric patients two years of ...
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous...
David Ricks, CEO of Eli Lilly and Co (NYSE:LLY), expressed confidence in meeting the lofty revenue expectations set by Bank of America for the comp...
A team of Chinese scientists has successfully cured a patient’s diabetes using cell therapy, marking a global first. What Happened: The patie...
Tesla and SpaceX CEO Elon Musk made a bold prediction about the future cost of Novo Nordisk’s (NYSE:NVO) Ozempic, a popular drug being used ...
Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufa...
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Arista Networks, Inc. (NYSE:ANET) reported an “unbelievable” qu...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...